IL13 and chronic obstructive pulmonary disease: Conversely, the BOREAS and NOTUS studies, which investigated anti-IL-4/IL-13 therapies, enrolled COPD patients with a blood eosinophil count of 300 cells per microliter or higher to receive subcutaneous Dupilumab or a placebo biweekly [91,92].